Vitamin D and calcium cut cancer risk, says trial

15 July 2007

The results of two recently-published independent studies suggest that improved nutritional status via vitamin D and calcium supplementation may substantially reduce a woman's risk of developing cancer. The findings provide further support for the idea that optimal intake of such nutrients is of benefit in preventing the development of serious disease.

Cuts breast cancer risk 35%

The first assessment, details of which were presented in the Archives of Internal Medicine, examined nutritional and dietary information from 10,000 pre- and 20,000 postmenopausal cancer-free women for a 10-year period. Analysis revealed that a higher intake of both vitamin D and calcium was associated with a reduced likelihood of breast cancer; in the sub-population that had the highest intake of both nutrients for example, the risk reduction was around 35%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight